NCT00448279View on ClinicalTrials.gov

THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

PHASE3CompletedINTERVENTIONAL

Enrollment

58

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Breast Cancer

Interventions

DRUG

trastuzumab

2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks

DRUG

Chemotherapy

Schedule and dose at the investigator's discretion

Trial Locations (35)

10060

Candiolo

10125

Torino

16132

Genova

25123

Brescia

27100

Pavia

33100

Udine

33170

Pordenone

35128

Padua

44124

Cona (Ferrara)

46100

Mantova

47014

Meldola

50139

Florence

54033

Carrara

57100

Livorno

61032

Fano

71013

San Giovanni Rotondo

73100

Lecce

80026

Frattaminore

80131

Napoli

83100

Avellino

84014

Nocera Inferiore

84131

Salerno

85028

Rionero in Vulture

85100

Potenza

87100

Cosenza

88900

Crotone - Kr

89100

Reggio Calabria

90127

Palermo

97100

Ragusa

98030

Taormina

06122

Perugia

00128

Roma

00153

Roma

07100

Sassari

03039

Sora

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00448279 - THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. | Biotech Hunter | Biotech Hunter